AIRLINK 75.50 Decreased By ▼ -4.50 (-5.63%)
BOP 5.18 No Change ▼ 0.00 (0%)
CNERGY 4.48 Increased By ▲ 0.02 (0.45%)
DFML 34.90 Decreased By ▼ -0.26 (-0.74%)
DGKC 77.70 Increased By ▲ 0.82 (1.07%)
FCCL 20.15 Increased By ▲ 0.17 (0.85%)
FFBL 37.21 Increased By ▲ 1.61 (4.52%)
FFL 9.55 Increased By ▲ 0.02 (0.21%)
GGL 10.00 Decreased By ▼ -0.16 (-1.57%)
HBL 117.30 Increased By ▲ 0.30 (0.26%)
HUBC 133.19 Increased By ▲ 0.69 (0.52%)
HUMNL 7.02 Decreased By ▼ -0.04 (-0.57%)
KEL 4.58 Decreased By ▼ -0.07 (-1.51%)
KOSM 4.55 Decreased By ▼ -0.10 (-2.15%)
MLCF 37.19 Decreased By ▼ -0.31 (-0.83%)
OGDC 136.80 Increased By ▲ 2.33 (1.73%)
PAEL 23.28 Increased By ▲ 0.38 (1.66%)
PIAA 26.83 Increased By ▲ 0.20 (0.75%)
PIBTL 6.80 Decreased By ▼ -0.01 (-0.15%)
PPL 117.70 Increased By ▲ 5.60 (5%)
PRL 27.57 Increased By ▲ 0.37 (1.36%)
PTC 14.43 Increased By ▲ 0.05 (0.35%)
SEARL 56.20 Decreased By ▼ -0.19 (-0.34%)
SNGP 68.45 Increased By ▲ 1.45 (2.16%)
SSGC 10.84 Increased By ▲ 0.01 (0.09%)
TELE 9.20 Decreased By ▼ -0.09 (-0.97%)
TPLP 11.02 Decreased By ▼ -0.16 (-1.43%)
TRG 67.35 Decreased By ▼ -1.65 (-2.39%)
UNITY 25.34 Decreased By ▼ -0.15 (-0.59%)
WTL 1.33 Increased By ▲ 0.01 (0.76%)
BR100 7,582 Increased By 59.9 (0.8%)
BR30 24,701 Increased By 298.8 (1.22%)
KSE100 72,093 Increased By 397.6 (0.55%)
KSE30 23,711 Increased By 168.9 (0.72%)

LONDON: European equities fell in opening deals on Tuesday after the head of Moderna warned current coronavirus vaccines might be less effective at fending off the Omicron variant.

In initial trade, London’s benchmark FTSE 100 index reversed 0.9 percent to 7,047.14 points.

In the eurozone, Frankfurt’s DAX shed 0.9 percent to 15,137.86 points and the Paris CAC 40 lost 1.1 percent to 6,702.83.

Asian bourses and oil prices also took a tumble following the remarks.

Moderna chief executive Stephane Bancel’s comments, in an interview with the Financial Times, sent traders running for cover.

“There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,” he told the daily business newspaper.

The high amount of mutations on Omicron and its swift spread in South Africa indicated the present jabs would need to be tweaked, he indicated.

“Bancel ... predicted existing vaccines would struggle with the Omicron variant,” said CMC Markets analyst Michael Hewson.

The Moderna chief “warned it would take months for pharmaceutical companies to manufacture enough jabs at a sufficient scale to make a difference”, Hewson added.

“His tone contrasts with the likes of Pfizer and BioNTech was suggested any new vaccine would be able to modified fairly quickly.”

Comments

Comments are closed.